Page 374«..1020..373374375376..380390..»

Category Archives: Transhuman News

Itch Relief – National Eczema Association

Posted: April 27, 2022 at 10:01 am

Chronic itchy skin is a universal symptom of most types of eczema. Itch from eczema is different than itch from a bug bite or poison ivy. Because of this, common medications used for itch, such as antihistamines, do not work well on the itch associated with eczema.

For many people, chronic itch from eczema goes way beyond just the physical. People with chronically itchy skin are more likely to experience poor sleep, and mental health issues such as depression and anxiety.

According to researchers, itch and pain have a yin-yang relationship. When pain is present, the feeling of itch subsides. Thats why scratching can relieve the feeling of itchy skin because it causes low-grade pain.

The first step to managing itchy skin is to reduce the risk of it happening in the first place. This can be done through a daily bathing and moisturizing routine and using prescription medications as prescribed. Wet wrap therapy also helps control itch. Outside of bathing, apply moisturizers that replenish the skin barrier consistently and liberally throughout the day.

Natural remedies for itch relief include soaking in a bath with oatmeal or baking soda. These can also be applied directly to the skin in the form of a paste.

While antihistamines do not stop the itch sensation, they may be recommended to help people with eczema fall asleep. Cotton gloves or cutting finger nails short can help protect the skin from night-time scratching. OTC corticosteroids can also help with mild itch.

Topical and immunosuppressant medications reduce symptoms of itch as does phototherapy. In severe cases, health care providers may prescribe mirtazapine, an antidepressant that is effective at relieving itch at night; pramoxine, a topical anesthetic; or certain oral antibiotics used for skin infections.

As much as possible, try not to excessively scratch the skin affected by an eczema flare. Too much scratching can lead to more rashes, thickened skin and infections if the surface of the skin is broken. Scratching also can trigger the itch-scratch cycle where the scratching leads to more itchiness.

Learn more about the mechanisms of itch and how to manage it in our webinar Starting From Scratch with Timothy Berger, MD.

For some adults with eczema, the intense itching can lead to a diagnosis of the skin disorder, neurodermatitis (nur-OH-dur-muh-TIE-tis), sometimes called lichen simplex chronicus (LIEken SIM-plex KRON-ik-cus).

Neurodermatitis is fueled by the itch-scratch cycle. The affected patch of skin becomes thick, leathery and even itchier the more it is rubbed or scratched because of irritated nerve endings in the skin. The affected skin may also appear darker than the skin around it and have pronounced lines. Once the itching is brought under control and the skin heals, the symptoms of neurodermatitis typically improve.

Read more about neurodermatitis.

Here is the original post:
Itch Relief - National Eczema Association

Posted in Eczema | Comments Off on Itch Relief – National Eczema Association

A Carefully Considered Morning Ritual That Can Brighten Your Day – Verve Times

Posted: at 10:01 am

Raelle Brown is a powerful voice for many for women of color, for women with eczema, and for anyone needing a role model with strength and self-assurance. A video producer in the Philadelphia area, Raelle uses her communication skills and her deep compassion to help others through her popular Instagram account, @wokewithinskin, as well as her blog. How does she get ready to be at her best each morning, even when dealing with a difficult skin flare-up? Here, she shares her strategies, from both health/beauty and emotional perspectives.

As Raelle sees it, planning for any contingency is key. I have two different plans when it comes to a morning ritual because of my eczema, she says. My first plan is for the worst of times when Im having a flare-up. On days when Im actively dealing with myeczema, I cant rely on being able to do everything in the morning it might be too uncomfortable to do my usual cleansing and preparation. My solution is to do as much as I comfortably can the night before, in case my skin is really irritated the next day. I dont take a shower if Im having a flare-up, because it would make my skin way too dry. Instead, I fill a bath with Epsom salts and soak for about 20 minutes. Epsom salts exfoliate the skin, and they contain magnesium, a natural moisturizer. Plus, theyre very accessible for everyone, because theyre so inexpensive, she says.

Extra moisturizing is her next essential step. After I get out of the bathtub, I like to use natural butters jojoba especially is my go-to, Raelle explains. I know a lot of people use things like Vaseline, assuming its moisturizing, but its a chemical, and its so much more soothing to go with products that arent made up of chemicals. Then I use body oil all over, a natural formula again.

Next, she adapts her beauty routine. If Im having a flare-up, the only makeup Ill put on is lipstick the cleanest type I can find, Raelle says. I dont have just one brand that I like, but I find fruit-based formulas are the best for keeping my skin soft and calm. I try never to wear foundation, because I think with eczema its important to let your skin breathe as much as possible. For sure I wouldnt wear it during a flare-up trying to cover that just makes it more uncomfortable.

Then there are what Raelle calls her maintenance mornings. If Im not having an active flare-up, I might get up and decide to take a shower, then do my moisturizer and oil, she says. Or I might decide to skip a shower entirely, and outside of moisturizing I might just let my skin chill for a day. Chilling is a really good preventative step you can take sometimes. If I have to wear a little makeup for some reason, like Im going to have my photo taken for my blog or something like that, then I will put on a little makeup. But again, natural products all the way.

Thats what Raelle does for her body and then theres what she does to prepare herself psychologically for the day. I think its so helpful to just feel community support. That makes a huge difference in what you put out to the world externally, as well as how you feel internally, she reflects. So I go on social media, and I get support, and it is just a huge help to communicate with other people who are going through what I am, in dealing with eczema. It has helped me process so many things in such a therapeutic way.

To center herself, Raelle also does breath work. Just deep breathing, being conscious of your breath, being quiet if you cant do anything else to get ready for the day, doing that is so important, she says. In fact, anything you can do to be calm is important with eczema, calm is your superpower. Not just so you can deal well with flare-ups, or prevent them. I think, especially for women of color, you have to be aware of how the outside world is going to view you. Being calm, and aware of yourself internally, really helps, because our skin color is already judged, and then you have eczema in addition to that. Instead of being seen as unattractive, you have to be an inspiration. You have to know youre beautiful! Your viewpoint is the one that matters.

As Raelle tells it, these simple actions have empowered and sustained her for years. When I was at my lowest, dealing with the external effects of eczema, I had to learn to go beyond the external, she says. I had to find other answers. Finding other people like me motivated me. Now I know how to give that support back to others, and doing that through Instagram, through my blog, through just talking to them is the most important thing I do every morning and every day.

Read original article here

Follow this link:
A Carefully Considered Morning Ritual That Can Brighten Your Day - Verve Times

Posted in Eczema | Comments Off on A Carefully Considered Morning Ritual That Can Brighten Your Day – Verve Times

Can cancer cause itchy skin? Types, treatment, and other causes – Medical News Today

Posted: at 10:01 am

Itchy skin, or pruritus, can have many causes, and most are harmless. However, itchy skin can also be a symptom of certain types of cancer or a side effect of some cancer treatments.

The sensation of itchy skin can be irritating and uncomfortable. Also, repeated scratching can lead to complications, such as open sores and wounds that are painful and increase the risk of infection.

People who experience persistent itching should contact a doctor for diagnosis and treatment.

In this article, we list types of cancer that may cause itchy skin, and provide tips on managing this skin condition. We also outline some other causes of itchy skin and offer advice on when to consult a healthcare professional.

A 2018 study involving 16,925 people found that the participants with generalized skin itching, or pruritus, were more likely to also have cancer than those who did not have pruritus.

The researchers note that pruritus is most strongly associated with the following types of cancer:

The researchers also note that Black people with pruritus are more likely than white people to have skin, soft tissue, and blood cancers. By contrast, white people are at greater risk of developing liver, respiratory, gastrointestinal (GI), and gynecologic cancers.

Below, we discuss in more detail the types of cancer that may cause pruritus.

Health experts associate skin cancer more commonly with skin changes than with itchiness.

However, cancer can stimulate nerve endings in the skin, causing itching.

Lymphoma is a type of cancer that affects the lymphatic system, which is a network of organs, glands, and vessels that plays an important role in immunity. Specifically, lymphoma affects white blood cells called lymphocytes.

Itching is a common symptom of a group of lymphomas called cutaneous T-cell lymphomas. Itching may be due to nerve endings reacting to chemicals that the immune system releases in response to the lymphoma.

Polycythemia vera (PV) is a type of blood condition that causes the body to produce too many red blood cells, white blood cells, or platelets. Experts do not know the exact cause of PV, although most agree that it stems from a genetic mutation.

Itchy skin is one of the symptoms of PV and typically occurs when the skin comes into contact with water.

This type of pruritus likely occurs because of an overproduction of immune cells that trigger the release of chemicals called histamines. The histamines then cause allergic symptoms, such as itchy skin.

Some cancers of the digestive system, such as GI stromal tumors, may cause pruritus. However, if there are no other accompanying symptoms, an alternative diagnosis is more likely.

With GI cancers, pruritus occurs due to blockage of the bile ducts connecting the liver and the small intestine. This blockage prevents the normal drainage of fluid from the blood into the intestines. These chemicals can then enter the skin, where they may trigger itching.

While certain cancer types can lead to itchy skin, cancer is not the most common cause of this symptom. However, if cancer is the underlying cause, a person will most likely experience additional symptoms.

Numerous skin conditions can result in itchy skin, such as:

Other possible causes of itchy skin include:

People may be able to manage itchy skin using home remedies, medical treatments, or a combination of the two.

Some tips for managing itchy skin at home include:

A person who experiences severe or persistent skin itching should contact a doctor.

Depending on the persons symptoms, the doctor may order tests such as:

The type of treatment a doctor recommends for skin itching will depend on the underlying cause. Possible treatment options include:

Itchy skin can occur as a side effect of certain cancer treatments, including:

A person may also develop skin itching as a side effect of medications they take alongside primary cancer treatments. These medications may include:

A person should seek guidance from a healthcare professional if they experience itching that lasts for more than 2 weeks, particularly if the itching occurs across the entire body and does not have an identifiable cause.

People should also contact a doctor if they experience any of the following symptoms in addition to itchy skin:

Itchy skin, or pruritus, can have many causes, and most cases are relatively benign or transient. However, itchy skin can also occur as a symptom of certain types of cancer or as a side effect of certain cancer treatments.

Treatment for itchy skin may include medicated creams or lotions, oral or topical steroids, or antihistamines. The type of medication a doctor prescribes will depend largely on the cause of the itching.

Anyone who experiences itching lasting more than 2 weeks should contact a doctor. This is especially important if other symptoms are present, such as skin rashes, skin sores, or jaundice.

A doctor will work to diagnose the cause of the symptoms and determine appropriate treatments.

Read more:
Can cancer cause itchy skin? Types, treatment, and other causes - Medical News Today

Posted in Eczema | Comments Off on Can cancer cause itchy skin? Types, treatment, and other causes – Medical News Today

Death toll rises to 13 in Poland mine accidents; 11 missing – Verve Times

Posted: at 10:01 am

The death toll from two coal mine accidents last week in southern Poland has risen to 13 after another injured miner died

ByThe Associated Press

26 April 2022, 12:41

2 min read

WARSAW, Poland The death toll from two coal mine accidents last week in southern Poland has risen to 13 after another injured miner died Tuesday, a doctor said.

The miner died at the Siemianowice Slaskie hospital, which specializes in treating burns, where 20 other coal mine workers were still being treated for injuries from methane gas blasts, Dr. Przemyslaw Strzelec said.

The mans death means that seven miners and rescuers were killed by repeated blasts Wednesday and Thursday at the Pniowek mine, near the Czech border.

The search for seven others who remain missing was suspended after Thursdays blasts hurt 10 rescuers.

In the nearby Borynia-Zofiowka mine, 13 teams of rescuers are searching for four miners gone missing after a tremor and methane gas discharge on Saturday. Six miners died in that accident.

Prosecutors have opened investigations into the accidents. The mines are operated by the Jastrzebska Spolka Weglowa, JSW.

Most Polish coal mines are in the southern Silesia region and many have a high presence of methane in the rock.

Some 70% of Polands energy comes from coal, a proportion that has been sharply criticized by the European Union and environmental groups who are concerned about CO2 emissions and meeting climate change goals.

Poland has been trying to scale down its use of coal. Prime Minister Mateusz Morawiecki recently said Poland has stopped coal imports from Russia and its ally Belarus in response to Moscows invasion of Ukraine.

For years Poland has been reducing its dependence on Russian energy sources that was built in communist-era times before 1990, when Poland was Russias satellite.

Follow all AP news about climate change issues at https://apnews.com/hub/climate

Read original article here

Follow this link:
Death toll rises to 13 in Poland mine accidents; 11 missing - Verve Times

Posted in Eczema | Comments Off on Death toll rises to 13 in Poland mine accidents; 11 missing – Verve Times

danish pavilion unveils transhuman installation ‘we walked the earth’ at venice art biennale – Designboom

Posted: April 25, 2022 at 5:25 pm

uffe isolottos we walked the earth at venice art biennale 2022

At the Venice Art Biennale 2022, the Danish pavilion presents the haunting transhuman installation We Walked the Earth created by Uffe Isolotto and curated by Jacob Lillemose. Spread over the entire pavilion, the piece welcomes visitors into a hyperrealistic world where images of Danish pastoral farm life mix with bizarre sci-fi elements, weaving a world of uncertainty. We Walked the Earth showcases a drama of life and death that focuses on a family of three centaurs. Struggling to cope with the challenges of our current ever-changing reality, the centaurs embody a state of turmoil between despair and hope, reflecting the profound ambiguity of todays world.

Uffe Isolotto, We Walked the Earth, Pavilion of Denmark, Biennale Arte, 2022

image courtesy of Ugo Carmeni (also head image)

We Walked the Earth by Uffe Isolotto (see more here) transforms the pavilion into a farmhouse-like space paved with field stones, filled with piles of eelgrass and horse manure. Visitors to the Venice Art Biennale 2022 (see more here) are able to traverse the pavilion and discover images reminiscent of an idyllic Danish country lifestyle.

Nevertheless, on closer examination, it becomes apparent that all these seemingly familiar elements are, in fact, altered and distorted. The traditional Danish farming tools that lie around within the interior are, in reality, curious reinterpretations. Whats more, in one of the rooms hangs a mutated ham, and unfamiliar species of farm crops are scattered across the rooms, oozing a blue fluid.

Uffe Isolotto, We Walked the Earth, Pavilion of Denmark, Biennale Arte, 2022

image courtesy of Ugo Carmeni

Amid these peculiar surroundings, two hyperrealistic centaur sculptures emerge as the protagonists of the installation. Their unusual form serves as a testimony of the dramatic and demanding process they had to endure in order to adapt to the new conditions of our changing world. Their faces, bodies, and hands are noticeably larger than an average human, and their skin is covered in unusual markings. Meanwhile, the same blue fluid that seeps out of the farm crops seems to be sustaining the centaur creatures through tubes, leaving viewers to wonder whether it is a heating agent, a form of nutrition, or a drug.

A drama of life and death plays out across the two main rooms of the pavilion. In one room, the male centaur has taken his own life, and can be found hanging from a chain suspended from the ceiling. In the adjacent room, the female centaur is lying on the floor, giving birth to a baby centaur that seems to be of a different hybrid than its parents. Its human hands are transfigured towards something unrecognizable, holding a promise for the future and foreboding hard times, at the same time.

Uffe Isolotto, We Walked the Earth, Pavilion of Denmark, Biennale Arte, 2022

image designboom

There is a deep uncertainty in understanding what has happened to the centaurs and the world they live in. Is it a tragic or hopeful situation, or perhaps both? mentions Uffe Isolotto. Even though the centaurs may not be real, we feel their struggle.

The present time we live in is becoming increasingly complex and unpredictable as we face a lot of challenging realities, whether ecological, political or existential. Theres much hope and despair in the air, and I want to make that a physical reality with this installation. the artist explains. We Walked the Earth also draws on experiences from my personal life that in a metaphorical sense resonate with more universal feelings and thoughts about life and death that I sense exist in the world today. he adds.

Uffe Isolotto, We Walked the Earth, Pavilion of Denmark, Biennale Arte, 2022

image designboom

Uffe Isolotto, We Walked the Earth, Pavilion of Denmark, Biennale Arte, 2022

image designboom

Read more:
danish pavilion unveils transhuman installation 'we walked the earth' at venice art biennale - Designboom

Posted in Transhuman | Comments Off on danish pavilion unveils transhuman installation ‘we walked the earth’ at venice art biennale – Designboom

There Is No New Normal – Caffeinated Thoughts

Posted: at 5:25 pm

There is only onegeometric normal: perpendicular, at a right (90 degree angle).

If you are building a wall, check to be sure the wall is normal (straight) with a plumb line. Thats a string with a lead weight on it that always points to the center of the earth and is perpendicular to the surface. If the wall deviates to the right or to the left it is unstable. It is easily knocked down and will bring down whatever is attached to it.

The most famous abnormal building is theLeaning Tower of Pisa. Built on an unstable foundation, it began to lean very early, and huge expense has been incurred through the centuries to keep it from falling over. At present, 800 tons of lead bricks on one side of the building serve as a counterweight. We can keep piling on lead bricks, but the building will fall apart someday because of the abnormal stresses on the masonry.

The tower is a great tourist attraction, but not useful as a buildingyou cant put furniture on the slanting floors.

Something as abnormal as that tower can be sustained, but it requires constant application of force. Take away the lead bricks, and the natural law of gravity brings the structure down.

In society, norms may be based on how the majority of people behave. Some variation is normal. Customs and fashions change, but basic facts of biology and human nature will reassert themselves if outside pressures to conform to unnatural behavior are removedunless too much damage has been done.

It is not normal to wear a face mask and stay six feet away from other human beings. As soon as the pressure is removed, the students, even at a Woke university, are maskless and interacting normallytalking, laughing, hugging. Their natural immune systems are functioning normally.

It is not normal to stay locked indoors. Without police coercion, people will go out when they think it essential or safe.

It is not normal to worry constantly about a virus that in most people is no worse than the flu. Once the daily case counts and death statistics stop, people may believe their eyes and ears telling them that most people are ok. Unless they have been turned into obsessive-compulsive germophobes.

It is not normal for people to bully or exclude or malign family members and friends who choose not to take a novel experimental injection. That takes constant propaganda portraying them as lifelong lepers. But once the mortar of human relations is weakened, will the masonry crumble?

It is not normal for public health officials to have dictatorial powers to wreck normal human activities, for years after an apparent emergency ends. It is not normal for officials, academics, medical societies, and doctors to suppressinformation about preventive measures(such as vitamin D and betadine or hydrogen peroxide mouthwash) or early out-patient treatment with repurposed drugs long approved as safe. It is not normal to deny care to unvaccinated patients. It is not normal to cover up adverse effects of new treatments. Censorship and extraordinary repression are required, at least until terrified people get used to their constrained lives and lose their will to resist.

The attempt to establish a new normal and smash the old goes far beyond the pandemic measures. It is a biologic fact that there are two sexes, and that one male and one female gamete (sperm and egg) are needed to make a new human being. It is normal for men and women to be attracted to each other and to long for a stable union. It is normal for parents, children, and biological relatives to love and be loyal to each other. Infidelity and betrayal are tragedies in world literature and common motives for murder.

But imperfect as these societal structures are, there is one normal and there are many abnormals. If not two natural sexes, there is a constantly multiplying number of humanly constructed genders. If not one man/one woman marriage, there are many variable relationships of atomized individuals.

If we throw away our plumb line, and try to normalize what is unprecedented or until recently thought deviant, what will happen to our structure? The experts think they can redo our psyches and even reengineer our DNA. We are being subjected to a massive, uncontrolled, nonconsented experiment. Past societies may have had dictatorship by a self-appointed health priesthood or pervasive homosexuality, transgenderism, and promiscuity. Where are they now?

If we let the experts prevail, will we have a brave new happy transhuman utopia? Or a pile of rubble?

Visit link:
There Is No New Normal - Caffeinated Thoughts

Posted in Transhuman | Comments Off on There Is No New Normal – Caffeinated Thoughts

How collaboration is driving the next wave of genomics – Fast Company

Posted: at 5:20 pm

In 2011, Ashley Van Zeeland, a researcher with a recent PhD in neuroscience, was working as a fellow at the Scripps Research Translational Institute when she met a young woman with a mysterious illness. The girls parents were frightened and felt isolated: They didnt know if their daughter would surviveand if she did, what kind of life she could expect. Van Zeeland was part of the team that sequenced the familys DNA and, utilizing a new technology in the field of informatics, identified a new gene that was responsible for the girls rare disorder. It was a pivotal moment for the parents, who found peace of mind knowing their daughter could expect a full life and join the small community of young survivors of the same illness.

It was a pivotal moment for Van Zeeland as well. Seeing knowledge and technology come together to change that familys life cemented her desire to further expand the enormous potential of genomics. Her path led her to Illumina, the San Diego-based biotech company with a mission to improve human health by unlocking the power of the genome. Their transformative work has earned Illumina a spot on Fast Companys list of the worlds Most Innovative Companies.

Illumina has been innovating genetic sequencing for more than 20 years. When the company introduced its first sequencer in 2006, the cost to sequence a single genome was $300,000. Today, that cost can be as low as $600.

Illuminas advances in genetic sequencing are reshaping medicine. Genetic sequencing has now allowed cancer patients to find treatment options specific to their tumors, doctors to anticipate adverse drug reactions and personalize medicine, public health agencies around the world to track and detect new COVID variants, and patients with rare diseases to more easily identify and treat their illnesses. The next wave of innovation includes nucleic medicine, gene- and cell-based therapies, and early diagnostic tests.

Our next moonshot is the $100 genome, a huge goal that really rallies everybody together and turns the innovation dials all the way up, says Van Zeeland, who is now Illuminas VP and head of Illumina Open Innovation. Our open innovation and philanthropic efforts will make sure these transformative innovations are actually getting out and changing lives.

Through Illumina Open Innovation, Illumina is investing in new startups and partnering in research efforts to develop solutions in areas such as rapid sequencing and data security. To really unlock the power of the genome is something we cant do alone, Van Zeeland says. Illumina Open Innovation is all about creating opportunities and structures to invite innovation in and work collaboratively to drive even farther on what this technology can do.

At the same time, Illuminas philanthropic arm is working to increase access to the technology. Illumina worked with the African Union, Africa CDC, and the Bill & Melinda Gates Foundation to help establish the Africa Pathogen Genomics Initiative (PGI). In April 2021, Illumina committed $60 million in sequencing capabilities to a global pathogen genomics initiative, which expands the Africa PGI model globally. It is invigorating to be part of this incredible brain trust with so many diverse skillsets working to unlock the potential of genomics, Van Zeeland says. I know that the next five years are going to be twice as impactful as the past 10. And that is exciting.

See the rest here:
How collaboration is driving the next wave of genomics - Fast Company

Posted in Gene Medicine | Comments Off on How collaboration is driving the next wave of genomics – Fast Company

Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING Platform – Business Wire

Posted: at 5:20 pm

SOMERVILLE, Mass.--(BUSINESS WIRE)--Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as GENE WRITING technology, announced today that it has raised over $300 million in Series C financing. Investors included a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA); Alaska Permanent Fund Corporation; Altitude Life Science Ventures; ARTIS Ventures; Cormorant Asset Management; Tesseras founder, Flagship Pioneering; Hanwha Impact Partners; Longevity Vision Fund; March Capital; SALT Fund; SoftBank Vision Fund 2; funds and accounts advised by T. Rowe Price Associates, Inc., and others including all of Tesseras existing institutional shareholders.

We are thankful for the support from our new partners and existing investors alike in this latest funding round. It is our belief that genetic medicine will be the most important next epoch in medicineoffering the ability to cure genetic diseases and to someday even prevent disease from occurring, said Geoffrey von Maltzahn, Ph.D., Co-Founder, Chief Executive Officer, and Board Director of Tessera Therapeutics. Todays announcement will help us realize the promise of GENE WRITING technology and our mission of curing disease by writing in the code of life.

While there have been many advancements in the area of genetic medicine over the past decade, Tesseras GENE WRITING platform is charting an entirely new courseone that aims to revolutionize genetic medicine as we know it, said Noubar Afeyan, Ph.D., Co-Founder and Chairman of Tessera Therapeutics and Founder and CEO of Flagship Pioneering. This latest funding round is a testament to the immense potential of this bioplatform to provide new treatments and cures to previously untreatable genetic diseases.

Tesseras GENE WRITING technology is designed to cure disease by writing in the code of life. The GENE WRITING platform can change any base pair to any other, make small insertions or deletions, and write entire genes into the genome with delivery of only RNA. This unlocks the potential to cure nearly any genetic disease, create life-changing medicines for other serious conditions such as cancer, and prevent illnesses with curative, scalable, and easily administered genetic medicines that could become a new modality in human healthcare.

GENE WRITING technology is inspired by natures genome architectsMobile Genetic Elements (MGEs)to overcome the limitations of gene editing and gene therapies. MGEs evolved to write new sequences of DNA into the genome, in contrast to nucleases like CRISPR which evolved to destroy DNA. Therefore, MGEs offer the potential for immense impact in genetic medicine by writing short and long therapeutic sequences of DNA into human cells. Tessera has designed, built, and tested tens of thousands of engineered and synthetic MGEs to create programmable GENE WRITING systems that can write and rewrite the genome with high-efficiency, specificity, and fidelity.

The Tessera team has developed a remarkable GENE WRITING platform that confers unique advantages over alternative genetic medicine technologies, including base editing, CRISPR, and gene therapies, said Vali Barsan, M.D., of SoftBank Investment Advisers. Having worked closely with the company over the past year, its hugely exciting to observe GENE WRITING catalyze a new category of genetic medicine.

For more information on Tessera Therapeutics, including how GENE WRITING technology works, partnership opportunities, and job openings, please visit http://www.tesseratherapeutics.com.

About Tesseras GENE WRITER Technology

Tesseras GENE WRITER tools are based on natures genome architects, Mobile Genetic Elements (MGEs)the most abundant class of genes across the tree of life, representing approximately half of the human genome. Tessera has evaluated tens of thousands of natural and synthetic MGEs to create GENE WRITER candidates with the ability to write therapeutic messages into the human genome. Tesseras research engine further optimizes the discovered GENE WRITER candidates for efficiency, specificity, and fidelityessentially compressing eons of evolution into a few months.

About Tessera Therapeutics

Tessera Therapeutics is pioneering GENE WRITING technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. The GENE WRITING platform allows the correction of single nucleotides, the deletion or insertion of short sequences of DNA, and the writing of entire genes into the genome, offering the potential for a new category of genetic medicines with broad applications both in vivo and ex vivo. Tessera Therapeutics was founded by Flagship Pioneering in 2018, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability. For more information about Tessera, please visit http://www.tesseratherapeutics.com.

About Flagship Pioneering

Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in more than $140 billion in aggregate value. To date, Flagship has deployed over $2.6 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 42 transformative companies, including Axcella Therapeutics (NASDAQ: AXLA), Codiak Biosciences (NASDAQ: CDAK) Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Foghorn Therapeutics (NASDAQ: FHTX), Indigo Ag, Moderna (NASDAQ: MRNA), Omega Therapeutics (NASDAQ: OMGA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology (NASDAQ: SANA), Seres Therapeutics (NASDAQ: MCRB), and Sigilon Therapeutics (NASDAQ: SGTX).

Here is the original post:
Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING Platform - Business Wire

Posted in Gene Medicine | Comments Off on Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING Platform – Business Wire

Syncona : FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus’ CAR T cell therapy, obe-cel, for the treatment of adult…

Posted: at 5:20 pm

LONDON, April 25, 2022 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead gene therapy obecabatagene autoleucel (obe-cel), a CD19-directed autologous chimeric antigen receptor (CAR) T therapy that is being investigated in the ongoing FELIX Phase 2 study of adult relapsed / refractory B-Acute Lymphocytic Leukemia (ALL).

The FDA grants RMAT designation to drug candidates in recognition of the therapy's potential to address significant unmet medical needs in patients with serious or life-threatening conditions. Similar to Breakthrough Therapy designation, RMAT designation provides a number of important benefits in the drug development process, including early interactions with the FDA and other actions to expedite development and review.

"We are very proud to have received RMAT designation, which is an important regulatory milestone for obe-cel," said Dr. Christian Itin, Chief Executive Officer of Autolus. "This supports our belief that obe-cel has the potential to address a serious unmet medical need. It will enable us to further optimize our development and regulatory process and desire to bring this potentially curative therapy to patients as quickly as possible."

obe-cel has previously been granted Priority Medicines (PRIME) designation by the European Medicines Agency (EMA) and Innovative Licensing and Access Pathway (ILAP) by the Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom.

# # #

About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, please visit http://www.autolus.com.

About obe-cel (AUTO1)

Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies. Designed to have a fast target binding off-rate to minimize excessive activation of the programmed T cells, obe-cel may reduce toxicity and be less prone to T cell exhaustion, which could enhance persistence and improve the ability of the programmed T cells to engage in serial killing of target cancer cells. In collaboration with Autolus' academic partner, UCL, obe-cel is currently being evaluated in a Phase 1 clinical trialsfor B-NHL. Autolus has progressed obe-cel to the FELIX trial, a potential pivotal trial for adult ALL.

About obe-celFELIX clinical trial

Autolus' FELIX Phase 1b/2 clinical trial of obe-cel is enrolling adult patients with relapsed / refractory B-precursor ALL. The trial had a Phase 1b component prior to proceeding to the single arm, Phase 2 clinical trial. The primary endpoint is overall response rate, and the secondary endpoints include duration of response, MRD negative CR rate and safety. The trial is designed to enroll approximately 140 patients across 34 of the leading academic and non-academic centers in the United States, United Kingdom and Europe. [NCT04404660]

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding Autolus' development of the obe-cel program; the future clinical development, efficacy, safety and therapeutic potential of its product candidates, including progress, expectations as to the reporting of data, conduct and timing and potential future clinical activity and milestones; expectations regarding the initiation, design and reporting of data from clinical trials; expectations regarding regulatory approval process for any product candidates; the collaboration between Autolus and Blackstone; the discovery, development and potential commercialization of potential product candidates including obe-cel using Autolus' technology and under the collaboration agreement; the therapeutic potential for Autolus in next generation product developments of obe-cel in B-cell malignancies; the potential and timing to receive milestone payments and pay royalties under the strategic collaboration; and the Company's anticipated cash runway. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, the risks that Autolus' preclinical or clinical programs do not advance or result in approved products on a timely or cost effective basis or at all; the results of early clinical trials are not always being predictive of future results; the cost, timing and results of clinical trials; that many product candidates do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; and the impact of the ongoing COVID-19 pandemic on Autolus' business. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Autolus' actual results to differ from those contained in the forward-looking statements, see the section titled "Risk Factors" in Autolus' Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 10, 2022, as well as discussions of potential risks, uncertainties, and other important factors in Autolus' subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Autolus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

Contact:

Olivia Manser

+44 (0) 7780 471568

o.manser@autolus.com

Julia Wilson

+44 (0) 7818 430877

j.wilson@autolus.com

Susan A. Noonan

S.A. Noonan Communications

+1-917-513-5303

susan@sanoonan.com

Read more from the original source:
Syncona : FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus' CAR T cell therapy, obe-cel, for the treatment of adult...

Posted in Gene Medicine | Comments Off on Syncona : FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus’ CAR T cell therapy, obe-cel, for the treatment of adult…

Blood test could reveal transition to cancer in people at risk – OHSU News

Posted: at 5:20 pm

Rowan Callahan, Elias Spiliotopoulos,and Thuy Ngo, Ph.D, inside their lab at OHSU Knight Cancer Research Building on Friday, April 22, 2022. (OHSU/Christine Torres Hicks)

Oregon Health & Science University scientists have devised an accurate and sensitive way to test blood to see if a pre-cancerous condition is escalating to outright cancer potentially enabling treatment early in tumor development when cancer is more likely to be curable.

The OHSU researchers focused on two common conditions that can precede highly lethal cancers: liver cirrhosis, which boosts the risk of liver cancer, and a precursor to the blood cancer multiple myeloma called MGUS, which stands for monoclonal gammopathy of undetermined significance.

If the findings hold up in larger clinical studies, they set the stage for a simple, affordable method to screen people at risk by taking a small blood sample a few times a year.

Our biomarker may recapitulate the transition to cancer, says Thuy Ngo, Ph.D., who led the research. Ngo is an assistant professor of molecular and medical genetics in the OHSU School of Medicine and a member of CEDAR, the OHSU Knight Cancer Institutes Cancer Early Detection Advanced Research Center.

Ngos team reported the findingstoday in the journal NPJ Precision Oncology.

Many competing groups are developing blood tests for cancer early detection, but most are focused on finding cancers in a general population. Ngo and coauthors say there is an unmet need for a blood test that can identify patients with pre-malignant conditions who require further intervention due to a higher likelihood of cancer incidence. In the case of cirrhosis and MGUS, some will progress to cancer, but many others will not. There currently is no reliable way to predict which cases will progress.

The blood test devised by Ngo and colleagues looks for molecules called messenger RNA, which convey instructions from genes. Each RNA molecule is built of chemical units arranged in a single strand like letters of an alphabet that spell out the message of a gene.

RNA routinely escape from cells and circulate in the blood, but unprotected, the free molecules quickly degrade; this makes it technically challenging to read the sequences of a mass of cell-free RNA collected from blood and make sense of it.

A few years ago, not many people believed cell-free messenger RNA could be reliably detected in the blood because it is prone to degradation, Ngo says. We found a way to handle it, and we are among the first to apply it in cancer and pre-cancer early detection.

In the new research, the team took blood samples from eight people with liver cancer, 10 with multiple myeloma, four with liver cirrhosis, eight with MGUS, and 20 non-cancer donors. They painstakingly sequenced the RNA from the samples to obtain a view of gene activity represented by the messenger molecules recovered from blood.

From this, they were able to identify patterns of gene activity in the different groups of people and build models to distinguish those with cancer from those with pre-malignant conditions, and from those without cancer.

The models were able to distinguish multiple myeloma blood samples from non-cancer samples with 90% accuracy, and multiple myeloma from its pre-malignant condition with 100% accuracy. They were able to distinguish liver cancer samples from non-cancer with 93 to 100% accuracy, and liver cancer from cirrhosis with 100% accuracy.

Experiments showed that the level of the cell-free RNA biomarkers displayed a gradual transition from non-cancerous states through pre-cancerous conditions and cancer. The researchers validated the biomarkers using a set of subjects different from the ones used to develop the models, and they proved highly accurate at distinguishing cancer from non-cancer.

This is promising, but the sample set is small, so we need to be modest here, Ngo cautions. Its still very early stage and further clinical validation will be needed.

The research lays the foundation for developing inexpensive assays that measure levels of cell-free RNA in blood for a small panel of genes that can differentiate cancer from pre-malignant conditions.You dont need any fancy equipment for doing this, Ngo says. Any central lab with standard equipment can do the work. Sophisticated sequencing was only required for the discovery work of identifying the telltale gene signatures.

Ngo and OHSU have filed a patent on their findings, and Ngo says she is talking with a company about a licensing deal to develop the technology. We have several directions to move it forward, she says.

Ngos priority is people at risk for liver cancer. One-quarter to one-third of adults in the U.S. have fatty liver disease, making them vulnerable to cirrhosis and liver cancer. Across the globe, infectious hepatitis puts enormous numbers of people in danger of developing liver cancer. This is why, Ngo says, the world needs a simple, affordable test to identify those at highest risk and monitor their health for the earliest signs of malignant growth.

This research was supported by grants from Oregon Health & Science University (CEDAR3250918), Cancer Research UK/OHSU (C63763/A27122), OCTRI (UL1TR000128), Kuni Foundation, Department of Defense (W81XWH2110853) and Susan G. Komen Foundation (CCR21663959).

Oregon Health & Science University has filed patent applications based on this work. The authors report no other competing interests.

Link:
Blood test could reveal transition to cancer in people at risk - OHSU News

Posted in Gene Medicine | Comments Off on Blood test could reveal transition to cancer in people at risk – OHSU News

Page 374«..1020..373374375376..380390..»